The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio

S&P Global’s AAA ratings for Johnson & Johnson and Microsoft highlight exceptional balance-sheet strength and resilience versus the U.S. sovereign AA+ rating. Microsoft posted Q3 FY2026 revenue of $82.89B, up 18.3% year over year, with EPS of $4.27 beating consensus and a $627B contracted backlog, though capex rose 84.4% to $30.88B as AI spending accelerated. Johnson & Johnson delivered Q1 2026 revenue of $24.06B, up 9.9%, with adjusted EPS of $2.70 beating estimates and full-year EPS guidance raised to $11.45-$11.65, while extending its dividend growth streak to 64 years.

Analysis

The real market signal here is not “two AAA names exist,” but that the highest-quality balance sheets are being rewarded for very different reasons: JNJ for cash-flow resilience with litigation noise, and MSFT for balance-sheet flexibility amid an unusually aggressive AI capex cycle. That creates a subtle factor split: defensive equity income is being concentrated in healthcare, while secular growth is being subsidized by the market’s willingness to look through capex so long as contracted demand remains visible. In other words, the AAA label matters most as a funding-cost advantage and downside backstop, not as a valuation catalyst.

Second-order effects matter more than the headline rating. MSFT’s capex intensity is effectively pulling through demand for semis, networking, power, and data-center infrastructure, but it also raises the bar for monetization; if AI revenue growth decelerates from triple digits to merely strong double digits over the next 2–4 quarters, the stock can de-rate even if the balance sheet stays pristine. JNJ’s clean credit profile, by contrast, should continue to attract duration-sensitive capital if rates stay elevated, and its dividend profile makes it a natural substitute for long-duration bonds in retirement accounts. That said, litigation risk means the market will pay up for certainty only until another adverse legal headline forces a reset.

The contrarian read is that both names may be less about “buy now” and more about “own on pullbacks.” MSFT is being punished for spending, not solvency; that tends to create better entry points once capex growth normalizes or one of the AI monetization milestones beats. JNJ’s multiple may already embed the safety premium, so upside likely comes from pipeline execution and continued litigation containment rather than multiple expansion. The market is not mispricing bankruptcy risk — it is debating the speed at which that safety deserves to compound into returns.

Key Decisions for Investors

• Buy MSFT on weakness tied to capex headlines; use a 3-6 month horizon and target a recovery trade if AI revenue growth remains above 50% and backlog conversion stays intact. Risk/reward favors long equity or call spreads over chasing strength.
• Hold/accumulate JNJ as a defensive income anchor on any 2-4% pullback over the next 1-3 months; the appeal is downside protection and dividend durability, not rapid multiple expansion.
• Pair trade: long JNJ / short a higher-beta healthcare name with litigation or reimbursement risk for a 2-3 quarter relative-value expression. The thesis is that capital will continue to crowd into the cleanest balance sheets as rates stay sticky.
• For growth portfolios, consider a basket long MSFT + semiconductor/data-center suppliers, but size it with a stop if MSFT capex growth stays above revenue growth for two consecutive quarters. The risk is that infrastructure spend outruns monetization and compresses returns on capital.
• Avoid initiating new short positions in either name; the AAA backstop makes downside asymmetric. If trading tactically, use put spreads only around litigation or earnings windows where headline risk can temporarily overwhelm fundamentals.